16 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of LX2761, a Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitor Restricted to the Intestinal Lumen, for the Treatment of Diabetes.
Lexicon Pharmaceuticals
Stimulation of cortical bone formation with thienopyrimidine based inhibitors of Notum Pectinacetylesterase.
Lexicon Pharmaceuticals
4H-Thieno[3,2-c]chromene based inhibitors of Notum Pectinacetylesterase.
Lexicon Pharmaceuticals
Design, synthesis, and in vivo activity of novel inhibitors of delta-5 desaturase for the treatment of metabolic syndrome.
Lexicon Pharmaceuticals
The discovery of potent agonists for GPR88, an orphan GPCR, for the potential treatment of CNS disorders.
Lexicon Pharmaceuticals
Novel inhibitors of the high-affinity L-proline transporter as potential therapeutic agents for the treatment of cognitive disorders.
Lexicon Pharmaceuticals
Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma.
Lexicon Pharmaceuticals
Discovery of a Type III Inhibitor of LIM Kinase 2 That Binds in a DFG-Out Conformation.
Lexicon Pharmaceuticals
Novel L-xylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
Lexicon Pharmaceuticals
Lead optimization and structure-based design of potent and bioavailable deoxycytidine kinase inhibitors.
Lexicon Pharmaceuticals
5-Fluorocytosine derivatives as inhibitors of deoxycytidine kinase.
Lexicon Pharmaceuticals
Substituted 3-(4-(1,3,5-triazin-2-yl)-phenyl)-2-aminopropanoic acids as novel tryptophan hydroxylase inhibitors.
Lexicon Pharmaceuticals
Novel class of LIM-kinase 2 inhibitors for the treatment of ocular hypertension and associated glaucoma.
Lexicon Pharmaceuticals
Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders.
Lexicon Pharmaceuticals